Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05079711
Other study ID # USUHS.2020-058
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 18, 2022
Est. completion date August 30, 2026

Study information

Verified date May 2024
Source Uniformed Services University of the Health Sciences
Contact Elizabeth A Kostas-Polston, PhD
Phone 301.295.1531
Email elizabeth.kostas-polston@usuhs.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method). Polymerase chain reaction (PCR) and sequencing of fungi will be used as an aid to explain the nature of the discrepancy in the case of discordant results between the lay user-performed SavvyCheck Vaginal Yeast Test and standard vaginal yeast culture and identification method for Candida.


Description:

The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method). Polymerase chain reaction (PCR) and sequencing of fungi will be used as an aid to explain the nature of the discrepancy in the case of discordant results between the lay user-performed SavvyCheck Vaginal Yeast Test and standard vaginal yeast culture and identification method for Candida. Primary Objective: The primary objective is to establish lay user performance criteria (sensitivity and specificity) of the SavvyCheck Vaginal Yeast Test in comparison to the Reference Method (vaginal Candida yeast culture) Secondary Objectives: 1. To determine the positive predictive value and negative predictive value of the lay user-performed SavvyCheck Vaginal Yeast Test in comparison to the Reference Method (vaginal Candida yeast culture) 2. To determine the concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. trained user-performed SavvyCheck Vaginal Yeast Test Exploratory Objectives: 1. To determine the concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. vaginal wet mount microscopy results 2. To determine the concordance between results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. PCR and sequencing 3. To determine the concordance between results determined by the Reference Method (vaginal Candida yeast culture) -vs. PCR and sequencing Primary Endpoints: Calculation of sensitivity and specificity of the lay user-performed SavvyCheck Vaginal Yeast Test as compared to the Reference Method (vaginal Candida yeast culture) Secondary Endpoints: 1. Calculation of positive and negative predictive value of lay user-performed SavvyCheck Vaginal Yeast Test results as compared to the Reference Method (vaginal Candida yeast culture) 2. Calculation of concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test results -vs. trained user-performed SavvyCheck Vaginal Yeast Test results Exploratory Endpoints: 1. Calculation of concordance between the results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. vaginal wet mount microscopy 2. Calculation of concordance between results determined by lay user-performed SavvyCheck Vaginal Yeast Test -vs. PCR and sequencing 3. Calculation of concordance between results determined by the Reference Method (vaginal Candida yeast culture) -vs. PCR and sequencing Women, aged 18 years and older, symptomatic and asymptomatic for vaginitis will be enrolled in the study. We estimate that it will require a total enrollment of up to 600 symptomatic women at all clinical sites combined, to achieve the target of at least n=216 Reference Method (vaginal Candida yeast culture) positives. In addition, a combined total of 320 asymptomatic women will be enrolled in the study from the four clinical sites combined, to achieve the target of at least n=170 Reference Method (vaginal Candida yeast culture) negatives. Three, large, regional, DoD military treatment facilities (MTFs) 1. Womack Army Medical Center (WAMC) at Fort Liberty; Fayetteville, NC 2. Landstuhl Regional Medical Center (LRMC); Landstuhl, Germany 3. Brooke Army Medical Center (BAMC); Fort Sam Houston, TX The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for the detection of Candida antigen in vaginal secretions sampled by a swab, as an aid for identification of vulvovaginal candidiasis as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for over-the-counter use.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date August 30, 2026
Est. primary completion date August 30, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: Symptomatic Women Symptomatic women include those women who present with a complaint consistent with symptoms of vaginitis (e.g., increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination). Enrollment will continue at each clinical site until our target number of 216 Reference Method (vaginal Candida yeast culture) positives have been collected. We estimate up to 600 symptomatic women will be enrolled to meet our target. Inclusion Criteria for Symptomatic Women 1. DoD Military Health System beneficiary 2. Have a healthcare appointment at a recruitment clinic 3. 18 years of age or older 4. Must speak and understand English 5. Able to provide informed consent 6. Women experiencing vaginal symptoms, including: increased discharge, itching, soreness and irritation, rash on the labia, and genital burning that may worsen during urination 7. Must determine the test is applicable to her based on her symptoms after she has read the outside device labeling (box label) Asymptomatic Women Asymptomatic women include those women who do not present with a complaint consistent with vaginitis. Enrollment will continue at each clinical site until our target number of 170 Reference Method (vaginal Candida yeast culture) negatives have been collected. We estimate up to 320 asymptomatic women will be enrolled to meet our target. Inclusion Criteria for Asymptomatic Women: 1. DoD Military Health System beneficiary 2. Have a healthcare appointment at a recruitment clinic 3. 18 years of age or older 4. Must speak and understand English 5. Able to provide informed consent 6. Healthy women appearing for routine care without symptoms of vaginal yeast infection Exclusion Criteria: If any of the following criteria are met, a potential subject will be excluded from the study: 1. Currently menstruating 2. History of any clinical therapies and/or interventions related to gender confirmation (transgender person) 3. Use of any vaginal medication, taken by mouth or vaginally, within the last 7 days 4. Use of any vaginal product within 24 hours, including contraception (cream, gel, or foam), or douching solutions NOTE: Women who currently have an intrauterine device (IUD) placed are eligible to participate

Study Design


Intervention

Device:
SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)
The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.

Locations

Country Name City State
Germany Landstuhl Regional Medical Center Landstuhl
United States Womack Army Medical Center Fort Bragg North Carolina
United States Brooke Army Medical Center Fort Sam Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
Uniformed Services University of the Health Sciences Savvyon Diagnostics Ltd.

Countries where clinical trial is conducted

United States,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Assess concordance between the lay user-performed SavvyCheck Vaginal Yeast test result -vs vaginal wet mount microscopy Calculation of concordance between the results between the lay user-performed SavvyCheck Vaginal Yeast Test -vs. vaginal wet mount microscopy 12 months
Other Assess concordance between the lay user-performed SavvyCheck Vaginal Yeast test result -vs. PCR and sequencing Calculation of concordance between the results between the lay user-performed SavvyCheck Vaginal Yeast Test -vs. PCR and sequencing 12 months
Other Assess concordance between the Reference Method results (vaginal yeast culture) -vs PCR and sequencing Calculation of concordance between the Reference Method (vaginal yeast culture) results -vs PCR and sequencing 12 months
Primary Assess sensitivity and specificity between lay user-performed SavvyCheck Vaginal Yeast Test result compared to the Reference Method (vaginal Candida yeast culture) Calculation of sensitivity and specificity of the lay user-performed SavvyCheck Vaginal Yeast Test as compared to the Reference Method (vaginal Candida yeast culture) 12 months
Secondary Assess positive and negative predictive values of the lay-user SavvyCheck Vaginal Yeast Test result as compared to the Reference Method (vaginal Candida yeast culture) Calculation of the positive and negative predictive values of lay user-performed SavvyCheck Vaginal Yeast Test results as compared to the Reference Method (vaginal Candida yeast culture). 12 months
Secondary Assess concordance between the lay user-performed SavvyCheck Vaginal Yeast test result and the trained user-performed result. Calculation of concordance between the lay use-performed and the trained user-performed SavvyCheck Vaginal Yeast test results. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05012852 - Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis N/A
Completed NCT02150655 - Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Phase 0
Completed NCT00755053 - Comparative Efficacy of Ovule vs Tablet Phase 3
Completed NCT02679456 - Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Phase 2
Completed NCT02242695 - Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Phase 4
Recruiting NCT06397248 - DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy
Completed NCT00895453 - Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) N/A
Completed NCT05327192 - VVC Sampling Study for Analysis Validation
Completed NCT05399641 - Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis Phase 3
Completed NCT01806623 - The Study Of Fluconazole For Vulvovaginal Candidiasis Phase 3
Completed NCT05507333 - Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis N/A
Completed NCT01144286 - Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Phase 2
Completed NCT00353561 - Diabetes Mellitus and Vulvovaginal Candidiasis Phase 3
Recruiting NCT05895162 - Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis. N/A
Not yet recruiting NCT06450990 - Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection Phase 1/Phase 2
Recruiting NCT05908682 - Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Completed NCT02203942 - Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis N/A
Completed NCT01926028 - Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Phase 1/Phase 2
Completed NCT00194324 - Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Phase 4
Completed NCT02866227 - TOL-463 Phase 2 Study for Vaginitis Phase 2